<DOC>
	<DOC>NCT00454688</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.</brief_summary>
	<brief_title>Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome</brief_title>
	<detailed_description>A randomized, dose-ranging, double-blind, placebo-controlled study designed to evaluate the efficacy and tolerability of three dose levels of asimadoline in subjects with IBS.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Males and females aged 1879 Must sign an ICF Females of childbearing potential must have a negative pregnancy test at screening and must adhere to contraception throughout the trial Must have been diagnosed with IBS as a result of having at least 6 months, not necessarily consecutive, in the preceding 12 months of recurrent symptoms of abdominal discomfort or pain associated with at least 2 of the following: 1)relieved with defecation; 2)onset associated with a change in stool frequency; 3)onset associated with a change in stool form Must demonstrate a willingness to comply with daily telephone diary entry Any subject with evidence of a biochemical or structural abnormality of the digestive tract or other comorbid illness that might impact the ability to interpret the safety and efficacy data Pregnant or breastfeeding females Refusal to discontinue prohibited concomitant medications Use of an investigational drug or participation in an investigational study within 30 days of screening Inability or unwillingness to use the touchtone telephone data entry system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Asimadoline</keyword>
</DOC>